Stock Events

Stock Events

Tempest Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Next
-0.24
0.09
0.43
0.76
Expected EPS
-0.23894920000000003
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3OS0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Tempest Therapeutics' oncology focus.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Tempest Therapeutics.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. is known for its strong presence in the oncology sector, competing with Tempest Therapeutics in developing cancer therapies.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in direct competition with Tempest Therapeutics.
Novartis
NVS
Mkt Cap279.67B
Novartis AG is a multinational pharmaceutical company with a significant focus on oncology, competing in the same market as Tempest Therapeutics.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG is a major player in the oncology market, with a wide range of cancer treatments that compete with Tempest Therapeutics.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC has a strong oncology portfolio, making it a key competitor in the cancer therapy market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, develops cancer drugs, competing with Tempest Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is involved in developing treatments for cancer, among other diseases, competing in the oncology space with Tempest Therapeutics.

About

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Show more...
CEO
Mr. Nicholas Maestas
Employees
24
Country
United States
ISIN
US87978U2078

Listings

MU
DE
3OS0.MU
F
DE
3OS0.F
STU
DE
3OS0.STU
XNAS
US
TPST

0 Comments

Share your thoughts

FAQ

What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tempest Therapeutics stocks are traded under the ticker 3OS0.MU.
When is the next Tempest Therapeutics earnings date?▼
Tempest Therapeutics is going to release the next earnings report on May 07, 2026.
How many employees does Tempest Therapeutics have?▼
As of May 06, 2026, the company has 24 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health & Wellness sector.
When did Tempest Therapeutics complete a stock split?▼
Tempest Therapeutics has not had any recent stock splits.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in Brisbane, United States.